Related Experiment Video
Updated: Sep 15, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
Jeffrey V Lazarus1,2,3, Paul N Brennan4, Henry E Mark2
1City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA.
Abstract:
Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.
Insights
Metabolic dysfunction-associated steatohepatitis (MASH) requires timely diagnosis and intervention. Expanding community-based diagnostics is crucial for preventing severe outcomes, especially in adults with obesity or type 2 diabetes.
Area of Science:
- Hepatology and metabolic disease research.
- Public health and diagnostic strategy development.
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) significantly contributes to illness and death.
- Timely diagnosis and intervention for MASH are currently lacking.
- Liver fibrosis stage is the primary factor influencing MASH prognosis.
Purpose of the Study:
- To highlight the urgent need for improved MASH diagnosis and care.
- To emphasize the link between MASH, obesity, and type 2 diabetes.
- To advocate for enhanced community-based diagnostic capabilities.
Main Methods:
- Analysis of MASH prevalence and risk factors.
- Review of current diagnostic and intervention strategies.
- Assessment of healthcare system needs in four countries.
Main Results:
- MASH affects one in six adults with moderate to advanced fibrosis, particularly those with obesity and/or type 2 diabetes.
- Current diagnostic and intervention approaches are insufficient.
- Significant gaps exist in community-based MASH diagnostic capabilities.
Conclusions:
- A paradigm shift in MASH diagnosis is necessary.
- Expanding community-based diagnostics can improve prevention, treatment, and care.
- Addressing MASH requires integrated strategies focusing on at-risk populations.
